Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data of miRNAs from PBMC of dogs infected with L. infantum

ABSTRACT: Leishmania (L.) infantum is the etiologic agent of visceral leishmaniasis (VL). In Brazil represents a serious public health problem. Studies have shown that regulation of immune response appears to depend on miRNAs. In canine VL due to cell immune suppression being determinant of disease progression, knowledge of miRNAs may be important for the pattern of change in immune response. Here, we suggest that post-transcriptional regulation, mediated by miRNAs, may play a role in immune response of dogs with VL.

ORGANISM(S): synthetic construct Canis lupus familiaris

PROVIDER: GSE105443 | GEO | 2018/06/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Expression data of miRNAs from splenic leukocytes of dogs infected with L. infantum

Project description:The disease visceral leishmaniasis (VL), caused by Leishmania (L.) infantum, its a serious public health problem in Brazil. Studies with miRNAs showed their regulation in the immune response, due to cell immune suppression to be determinant at disease progression, identify them is important for the mechanism of change in immune response. We suggest then, that miRNAs regulation at immune response of dogs with VL.

2019-12-29 | GSE112459 | GEO

Blood transcription profiling of infections of humans with Leishmania infantum.

2016-10-25 | GSE77528 | GEO

Blood transcription profiling of infections of humans with Leishmania infantum.

Project description:Gene expression profiling to address the effects of infection with Leishmania infantum during distinct clinical outcomes as active visceral leishmaniasis (VL), remission of disease and asymptomatic infection. Total RNA was extracted from whole-blood lysates obtained from VL patients, treated VL patients, asymptomatic individuals and uninfected controls. The aim was to evaluate gene expression signatures associated with protective and pathological responses.

2016-10-25 | E-GEOD-77528 | biostudies-arrayexpress

RNA-seq of whole blood samples from human visceral leishmaniasis compared to samples from healthy uninfected controls

Project description:To ascertain which genes are involved in pathogenesis of human visceral leishmaniasis (VL) caused by the protozoan parasite Leishmania infantum, we investigated the transcriptional profile of whole blood samples from patients diagnosed with active VL compared to healthy control samples.

2016-11-16 | E-MTAB-4902 | biostudies-arrayexpress

RNA-seq of whole blood samples from patients with visceral leishmaniasis.

Project description:To ascertain which molecular pathways underlying the pathogenesis of human visceral leishmaniasis (VL) caused by the protozoan parasite Leishmania infantum, we performed modular co-expression gene networks analysis using CEMiTool R package and the transcriptional profile of whole blood samples from patients diagnosed with active VL compared to VL-treated condition (cured patients) and to healthy control samples.

2018-01-25 | E-MTAB-6137 | biostudies-arrayexpress

RNA-seq of blood samples from patients diagnosed with visceral leishmaniasis and asymptomatic individuals (Brazil)

Project description:To ascertain which genes are involved in the outcome of Leishmania infantum infection and immunopathology of human visceral leishmaniasis (VL), we investigated the transcriptional profile of whole blood samples from patients diagnosed with active VL compared to asymptomatic individuals (positive serology for Leishmania, but without clinical signs of disease) and healthy control samples.

2020-08-06 | E-MTAB-8818 | biostudies-arrayexpress

Bulk mRNA-seq of blood samples of visceral leishmaniasis patients during active disease and after treatment (cured), asymptomatic individuals and healthy uninfected control volunteers.

Project description:To ascertain which genes are involved in the outcome of Leishmania infantum infections and immunopathology of human visceral leishmaniasis (VL), we investigated the transcriptional profile of whole blood samples from patients during active VL compared to the same patients 180 days after being treated, when they were considered clinically cured. Also, we compared VL transcriptional profile to asymptomatic individuals (positive serology for Leishmania, but without clinical signs of disease) and healthy uninfected control samples.

2022-03-10 | E-MTAB-11047 | biostudies-arrayexpress

Study of visceral leishmaniasis establishment - Gene expression from (un)infected (non-)vaccinated mouse spleen samples

Project description:Visceral leishmaniasis (VL) caused by Leishmania donovani and L. infantum is a potentially fatal disease. To date there are no registered vaccines for disease prevention despite the fact that several vaccines are in preclinical development. Thus, new strategies are needed to improve vaccine efficacy based on a better understanding of the mechanisms mediating protective immunity and mechanisms of host immune responses subversion by immunopathogenic components of Leishmania. In the present study, determination of the immune mechanisms related to infection or protective immune responses against VL using an experimental nanovaccine as a vaccine model was conducted through microarray analysis.

2019-11-19 | GSE134661 | GEO

Expression data from bone marrow derived DCs stimulated with different peptide-based nanovaccine formulations against L. infantum infection

Project description:Visceral leishmaniasis (VL), caused by Leishmania spp protozoan parasites, can provoke overwhelming and protracted epidemics, with high case–fatality rates. Despite extensive efforts towards the development of an effective prophylactic vaccine, no promising vaccine is available yet for humans. Multi-epitope peptide based vaccine development is manifesting as the new era of vaccination strategies against VL. Aim of the study was the design of chimeric peptides from immunogenic L. infantum proteins for encapsulation in PLGA nanoparticles (NPs) alone or in combination with MPLA adjuvant, or in PLGA NPs surface modified with an octapeptide mimicking TNF-alpha for DCs targeting, in order to construct a peptide-based nanovaccine. The in vitro evaluation of the above nanoformulations was performed in DCs isolated from HLA-A2.1 transgenic mice. Characterization of DCs transcriptional responses to these vaccine candidates via microarrays could improve our understanding of their mechanisms of action on DCs' functional differentiation and the type of adaptive immunity subsequently induced.

2016-12-24 | GSE92869 | GEO

In-depth proteomics analysis of a Leishmania infantum strain selected in vitro for miltefosine resistance

Project description:Visceral Leishmaniasis (VL) is a neglected disease caused Leishmania parasites. Although significant morbidity and mortality in tropical and subtropical regions of the world are associated to VL, low investment for developing new treatment measures is chronic. Moreover, resistance and treatment failure are increasing for the main medications, but the emergence of resistance phenotypes is poorly understood at the protein level. Here, we analyzed the development of resistance to miltefosine upon experimental selection in a L. infantum strain. Time to miltefosine resistance emergence was ~six months and label-free quantitative mass-spectrometry-based proteomics analyses revealed that this process involves a remodeling of components of the membrane and mitochondrion, with significant increase in oxidative phosphorylation complexes, particularly on complex IV and ATP synthase, accompanied by increased energy metabolism mainly dependent on β-oxidation of fatty acids. Proteins canonically involved in ROS detoxification did not contribute to the resistant process whereas sterol biosynthesis enzymes could have a role in this development. Also, changes in the abundance of proteins known to be involved in miltefosine resistance such as ABC transporters and phospholipid transport ATPase were detected. Together, our data show a more complete picture of the elements that make up the miltefosine resistance phenotype in L. infantum.

2022-05-20 | PXD031912 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data